Mike is a Senior Portfolio Manager with a sector focus on Healthcare Stocks, including Pharmaceutical, Medical Device and Healthcare Service Names. Mike joined the EFG New Captial team in 2016 and has been an investment analyst since 1995 and previously covered this area for all Mazama Capital Management strategies for 13 years. Prior to Mazama, he was a Senior Analyst covering health care technology and pharmaceutical outsourcing stocks at UBS. Previously, he worked as a Healthcare Analyst at CIBC World Markets. Mike started his career as Corporate Lending Officer at PNC Bank.
One of the largest pharmaceutical companies in the world, Pfizer’s name recognition has increased more recently thanks to the introduction of its COVID-19 vaccine. Over the last 12 months, shares of Pfizer’s stock have gained approximately 47%. To put that into context, consider that the benchmar
News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. How healthcare can insulate your portfolio from inflation | Trustnet